Email Alert RSS
Volume 15 Issue 2
Mar.  2024
Turn off MathJax
Article Contents
Abstract
References
Related Articles
LYU Zhengqin, ZHAO Yuhao, GUO Yuanyuan, LIU Beibei, LIU Jianmin. Research Progress on the Effect of Clinical Concomitant Medication on Efficacy of Immune Checkpoint Inhibitors in Urothelial Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 394-399. DOI: 10.12290/xhyxzz.2023-0488
Citation: LYU Zhengqin, ZHAO Yuhao, GUO Yuanyuan, LIU Beibei, LIU Jianmin. Research Progress on the Effect of Clinical Concomitant Medication on Efficacy of Immune Checkpoint Inhibitors in Urothelial Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 394-399. DOI: 10.12290/xhyxzz.2023-0488
shu

Research Progress on the Effect of Clinical Concomitant Medication on Efficacy of Immune Checkpoint Inhibitors in Urothelial Carcinoma

  • Department of Urology, First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

More Information
  • Corresponding author:

    LIU Jianmin, E-mail: LIU-join-jm@sina.com

  • Received Date: October 20, 2023
  • Accepted Date: November 02, 2023
  • Available Online: January 02, 2024
  • Issue Publish Date: March 29, 2024
    Graphical Abstract
    • Abstract
  • Immune checkpoint inhibitors (ICIs) have been approved for the treatment of urothelial carcinoma(UC). However, the use of antibiotics, proton pump inhibitors, corticosteroids, beta-blockers, metformin, and statin concomitant medications in some patients due to complications during the treatment process may affect the clinical efficacy of ICIs through different pathway, making it difficult for patients to derive clinical benefit or making it more likely to develop drug resistance. In this paper, we present a review of the effects of the above concomitant drugs on ICIs in the treatment of patients with advanced UC, with a view to provide reference for the application of individualized treatment strategies of ICIs in patients with advanced UC.
    • FullText(HTML)
    • References (52)
  • [1]
    Kim T K, Herbst R S, Chen L P. Defining and unders-tanding adaptive resistance in cancer immunotherapy[J]. Trends Immunol, 2018, 39(8): 624-631. DOI: 10.1016/j.it.2018.05.001
    [2]
    Hopkins A M, Kichenadasse G, Karapetis C S, et al. Concomitant antibiotic use and survival in urothelial carcinoma treated with atezolizumab[J]. Eur Urol, 2020, 78(4): 540-543. DOI: 10.1016/j.eururo.2020.06.061
    [3]
    Lopes S, Pabst L, Dory A, et al. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis[J]. Front Immunol, 2023, 14: 1070076. DOI: 10.3389/fimmu.2023.1070076
    [4]
    Drakaki A, Dhillon P K, Wakelee H, et al. Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune check-point inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma[J]. Oncoimmunology, 2020, 9(1): 1824645. DOI: 10.1080/2162402X.2020.1824645
    [5]
    Kokolus K M, Zhang Y, Sivik J M, et al. Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice[J]. Oncoimmunology, 2018, 7(3): e1405205. DOI: 10.1080/2162402X.2017.1405205
    [6]
    Fiala O, Buti S, Takeshita H, et al. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study[J]. Cancer Immunol Immunother, 2023, 72(11): 3665-3682. DOI: 10.1007/s00262-023-03518-z
    [7]
    Weersma R K, Zhernakova A, Fu J Y. Interaction between drugs and the gut microbiome[J]. Gut, 2020, 69(8): 1510-1519. DOI: 10.1136/gutjnl-2019-320204
    [8]
    Matson V, Fessler J, Bao R Y, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients[J]. Science, 2018, 359(6371): 104-108. DOI: 10.1126/science.aao3290
    [9]
    Ubeda C, Pamer E G. Antibiotics, microbiota, and immune defense[J]. Trends Immunol, 2012, 33(9): 459-466. DOI: 10.1016/j.it.2012.05.003
    [10]
    Tsikala-Vafea M, Belani N, Vieira K, et al. Use of antibiotics is associated with worse clinical outcomes in patients with cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis[J]. Int J Infect Dis, 2021, 106: 142-154. DOI: 10.1016/j.ijid.2021.03.063
    [11]
    Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science, 2018, 359(6371): 91-97. DOI: 10.1126/science.aan3706
    [12]
    Wu Q, Liu J J, Wu S M, et al. The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: a study based on 44 cohorts[J]. Int Immunopharmacol, 2021, 92: 107303. DOI: 10.1016/j.intimp.2020.107303
    [13]
    Sivan A, Corrales L, Hubert N, et al. Commensal Bifido-bacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy[J]. Science, 2015, 350(6264): 1084-1089. DOI: 10.1126/science.aac4255
    [14]
    Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients[J]. Science, 2018, 359(6371): 104-108. DOI: 10.1126/science.aao3290
    [15]
    Casadei C, Lolli C, Farolfi A. Immune-checkpoint inhibitors and the importance of concomitant medications: focus on antibiotics[J]. Ann Transl Med, 2019, 7(Suppl 8): S339.
    [16]
    Rosa R G, Goldani L Z, Dos Santos R P. Association between adherence to an antimicrobial stewardship program and mortality among hospitalised cancer patients with febrile neutropaenia: a prospective cohort study[J]. BMC Infect Dis, 2014, 14: 286. DOI: 10.1186/1471-2334-14-286
    [17]
    Routy B, Gopalakrishnan V, Daillère R, et al. The gut microbiota influences anticancer immunosurveillance and general health[J]. Nat Rev Clin Oncol, 2018, 15(6): 382-396. DOI: 10.1038/s41571-018-0006-2
    [18]
    Esteves M, Rollason V, Grosgurin O. Proton pump inhibi-tors overprescription[J]. Rev Med Suisse, 2017, 13(579): 1782-1786.
    [19]
    Reveles K R, Ryan C N, Chan L, et al. Proton pump inhibitor use associated with changes in gut microbiota composition[J]. Gut, 2018, 67(7): 1369-1370. DOI: 10.1136/gutjnl-2017-315306
    [20]
    Hojo M, Asahara T, Nagahara A, et al. Gut microbiota composition before and after use of proton pump inhibitors[J]. Dig Dis Sci, 2018, 63(11): 2940-2949. DOI: 10.1007/s10620-018-5122-4
    [21]
    Hopkins A M, Kichenadasse G, Karapetis C S, et al. Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab[J]. Clin Cancer Res, 2020, 26(20): 5487-5493. DOI: 10.1158/1078-0432.CCR-20-1876
    [22]
    Zhang L L, Chen C, Chai D Q, et al. Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy[J]. Front Pharmacol, 2022, 13: 1018411. DOI: 10.3389/fphar.2022.1018411
    [23]
    Rizzo A, Santoni M, Mollica V, et al. The impact of concomitant proton pump inhibitors on immunotherapy efficacy among patients with urothelial carcinoma: a meta-analysis[J]. J Pers Med, 2022, 12(5): 842. DOI: 10.3390/jpm12050842
    [24]
    Okuyama Y, Hatakeyama S, Numakura K, et al. Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma[J]. BJUI Compass, 2022, 3(2): 154-161. DOI: 10.1002/bco2.118
    [25]
    Kunimitsu Y, Morio K, Hirata S, et al. Effects of proton pump inhibitors on survival outcomes in patients with metastatic or unresectable urothelial carcinoma treated with pembrolizumab[J]. Biol Pharm Bull, 2022, 45(5): 590-595. DOI: 10.1248/bpb.b21-00939
    [26]
    Gong J, Chehrazi-Raffle A, Placencio-Hickok V, et al. The gut microbiome and response to immune checkpoint inhibi-tors: preclinical and clinical strategies[J]. Clin Transl Med, 2019, 8(1): 9. DOI: 10.1186/s40169-019-0225-x
    [27]
    Gopalakrishnan V, Spencer C N, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients[J]. Science, 2018, 359(6371): 97-103. DOI: 10.1126/science.aan4236
    [28]
    Laheij R J F, Sturkenboom M C J M, Hassing R J, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs[J]. JAMA, 2004, 292(16): 1955-1960. DOI: 10.1001/jama.292.16.1955
    [29]
    Skribek M, Rounis K, Afshar S, et al. Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors[J]. Eur J Cancer, 2021, 145: 245-254. DOI: 10.1016/j.ejca.2020.12.012
    [30]
    Petrelli F, Signorelli D, Ghidini M, et al. Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. Cancers (Basel), 2020, 12(3): 546. DOI: 10.3390/cancers12030546
    [31]
    Chen C Y, Rao S S, Yue T, et al. Glucocorticoid-induced loss of beneficial gut bacterial extracellular vesicles is associated with the pathogenesis of osteonecrosis[J]. Sci Adv, 2022, 8(15): eabg8335. DOI: 10.1126/sciadv.abg8335
    [32]
    Fucà G, Galli G, Poggi M, et al. Modulation of peripheral blood immune cells by early use of steroids and its associa-tion with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors[J]. ESMO Open, 2019, 4(1): e000457. DOI: 10.1136/esmoopen-2018-000457
    [33]
    Spakowicz D, Hoyd R, Muniak M, et al. Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications[J]. BMC Cancer, 2020, 20(1): 383. DOI: 10.1186/s12885-020-06882-6
    [34]
    Ricciuti B, Dahlberg S E, Adeni A, et al. Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications[J]. J Clin Oncol, 2019, 37(22): 1927-1934. DOI: 10.1200/JCO.19.00189
    [35]
    Horvat T Z, Adel N G, Dang T O, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center[J]. J Clin Oncol, 2015, 33(28): 3193-3198. DOI: 10.1200/JCO.2015.60.8448
    [36]
    Robesti D, Nocera L, Belladelli F, et al. The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: analysis of individual patient data from IMvigor210 and IMvigor211 trials[J]. BJU Int, 2024, 133(2): 158-168. DOI: 10.1111/bju.16121
    [37]
    Maxwell R, Luksik A S, Garzon-Muvdi T, et al. Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nerv-ous system[J]. Oncoimmunology, 2018, 7(12): e1500108. DOI: 10.1080/2162402X.2018.1500108
    [38]
    Oh M S, Guzner A, Wainwright D A, et al. The impact of beta blockers on survival outcomes in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors[J]. Clin Lung Cancer, 2021, 22(1): e57-e62. DOI: 10.1016/j.cllc.2020.07.016
    [39]
    Bucsek M J, Qiao G X, MacDonald C R, et al. β-adren-ergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8+ T cells and under-mines checkpoint inhibitor therapy[J]. Cancer Res, 2017, 77(20): 5639-5651. DOI: 10.1158/0008-5472.CAN-17-0546
    [40]
    Mellgard G, Patel V G, Zhong X B, et al. Effect of concurrent beta-blocker use in patients receiving immune check-point inhibitors for advanced solid tumors[J]. J Cancer Res Clin Oncol, 2023, 149(7): 2833-2841. DOI: 10.1007/s00432-022-04159-y
    [41]
    Rains S L, Amaya C N, Bryan B A. Beta-adrenergic receptors are expressed across diverse cancers[J]. Oncoscience, 2017, 4(7/8): 95-105.
    [42]
    Udumyan R, Botteri E, Jerlstrom T, et al. Beta-blocker use and urothelial bladder cancer survival: a Swedish register-based cohort study[J]. Acta Oncol, 2022, 61(8): 922-930. DOI: 10.1080/0284186X.2022.2101902
    [43]
    Scharping N E, Menk A V, Whetstone R D, et al. Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia[J]. Cancer Immunol Res, 2017, 5(1): 9-16. DOI: 10.1158/2326-6066.CIR-16-0103
    [44]
    Gandhi S, Pandey M, Ammannagari N, et al. Impact of concomitant medication use and immune-related adverse events on response to immune checkpoint inhibitors[J]. Immunotherapy, 2020, 12(2): 141-149. DOI: 10.2217/imt-2019-0064
    [45]
    Afzal M Z, Mercado R R, Shirai K. Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma[J]. J Immunother Cancer, 2018, 6(1): 64. DOI: 10.1186/s40425-018-0375-1
    [46]
    Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug[J]. Nat Med, 2017, 23(7): 850-858. DOI: 10.1038/nm.4345
    [47]
    Liu W H, Wang Y, Luo J Q, et al. Pleiotropic effects of metformin on the antitumor efficiency of immune checkpoint inhibitors[J]. Front Immunol, 2020, 11: 586760.
    [48]
    Zhang J J, Zhang Q S, Li Z Q, et al. Metformin attenuates PD-L1 expression through activating Hippo signaling pathway in colorectal cancer cells[J]. Am J Transl Res, 2019, 11(11): 6965-6976.
    [49]
    Kim H, Seol Y M, Choi Y J, et al. HMG CoA reductase expression as a prognostic factor in Korean patients with breast cancer: A retrospective study[J]. Medicine (Baltimore), 2019, 98(13): e14968. DOI: 10.1097/MD.0000000000014968
    [50]
    Cantini L, Pecci F, Hurkmans D, et al. Statin treatment improves response to anti-PD1 agents in patients with malignant pleural mesothelioma and non-small cell lung cancer[J]. J Clin Oncol, 2020, 38(15_suppl): 3074. DOI: 10.1200/JCO.2020.38.15_suppl.3074
    [51]
    Cantini L, Pecci F, Hurkmans D P, et al. High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients[J]. Eur J Cancer, 2021, 144: 41-48. DOI: 10.1016/j.ejca.2020.10.031
    [52]
    Choe E J, Lee C H, Bae J H, et al. Atorvastatin enhances the efficacy of immune checkpoint therapy and suppresses the cellular and extracellular vesicle PD-L1[J]. Pharmaceutics, 2022, 14(8): 1660. DOI: 10.3390/pharmaceutics14081660
    • Related Articles

  • Related Articles

    [1]NIMA Zhuoma, XIAO Yu, LUO Hanhuan, DUO Bula, WANG Han, DA Zhen, SILANG Jiangcun, GUO Pingping, LIAO Ruiqian. Expression and Significance of GATA-3, H3K27me3 in Tibetan Patients with Bladder Urothelial Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 953-959. DOI: 10.12290/xhyxzz.2023-0595
    [2]LI Tao, ZHANG Kan, YANG Wenyu, LIU Lu, ZHENG Xuan, ZHANG Fan, HU Yi. Clinical Application of Immune Checkpoint Inhibitors CTLA-4 in Solid Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(3): 652-659. DOI: 10.12290/xhyxzz.2022-0617
    [3]WANG Shuo, DENG Yuntian, PENG Huan, ZHANG Xiangfeng. Progress in the Treatment of Non-small Cell Lung Cancer with Immune Checkpoint Inhibitors[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 409-415. DOI: 10.12290/xhyxzz.2022-0151
    [4]YANG Tingkai, WEN Jin, JI Zhigang. The Value of Insulin-like Growth Factor 2 in Urinary Exosomes of Bladder Urothelial Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(4): 632-636. DOI: 10.12290/xhyxzz.2021-0446
    [5]DAI Liyuan, SHI Yuankai, HAN Xiaohong. Advances in Dynamic Monitoring of Immune Checkpoint Inhibitors as the Prognostic Markers for Advanced Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 287-295. DOI: 10.12290/xhyxzz.2021-0608
    [6]Gynecological Oncology Society of Chinese Medical Association. Clinical Practice Guidelines for Immune Checkpoint Inhibitor Therapy in Gynecological Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 854-880. DOI: 10.12290/xhyxzz.2021-0683
    [7]WU Ling-ge, XU Yan, LI Nai-shi. Thyrotoxicosis Related to Immune Checkpoint Inhibitors[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 129-135. DOI: 10.3969/j.issn.1674-9081.2020.00.004
    [8]Yang GAO, Zhao SUN, Chun-mei BAI. Application of Immune-checkpoint Inhibitors in Recurrent/Metastatic Nasopharyngeal Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 626-630. DOI: 10.3969/j.issn.1674-9081.2020.05.021
    [9]Hui TANG, Jian-feng ZHOU, Chun-mei BAI. Clinical Progress of Immune Checkpoint Inhibitors in the Elderly[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(4): 459-464. DOI: 10.3969/j.issn.1674-9081.2020.04.018
    [10]Jie SHI, Zhi-yong LIANG, Tong-hua LIU. Expression of Cyclin D1 in Invasive Lobular Carcinoma of the Breast and Its Significance[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(1): 8-12. DOI: 10.3969/j.issn.1674-9081.2012.01.004

  • Cited by

    Periodical cited type(9)

    1. 赵常安，卫灿红，郑进. 郑进教授基于“气血理论”辨治脓毒性休克经验. 中国民族民间医药. 2024(12): 89-93 .
    2. 王伟，张月辉，余保军，苏盛元，陈锐均，王立军. 龙虾爪征诊断左室流出道动态梗阻2例. 中华急诊医学杂志. 2024(05): 713-716 .
    3. 李硕思，王文清. 从《伤寒杂病论》中“死证症候群”谈现代重症医学对中医应用范围的拓展作用. 亚太传统医药. 2023(06): 186-191 .
    4. 潘宇杰，李莉，严静. 基于组织灌注的脓毒症休克复苏策略研究进展. 心脑血管病防治. 2022(02): 65-69+2 .
    5. 杨佳，李文斌，汪浩森. CD_(64)、肝素结合蛋白和降钙素原对感染性休克患儿的诊断及评估预后的价值. 中国医师进修杂志. 2022(07): 648-653 .
    6. 齐迪，万娜，赵明曦，谢铃莉，路经纬，田策，侯锦，孙建华，张春艳，李奇. 外周灌注指数监测在重症病人中的应用进展. 护理研究. 2022(19): 3485-3489 .
    7. 田昕，潘景业. 改善脓毒性休克微循环药物的研究进展. 实用休克杂志(中英文). 2022(03): 168-172 .
    8. 彭旭，尹海林. 实验外科复杂手术中巴马猪超长时间复合麻醉方案探索. 实验动物科学. 2022(05): 37-44 .
    9. 张玉奇，李小悦. 中心静脉-动脉二氧化碳分压差在休克评估中的研究进展. 中华卫生应急电子杂志. 2020(02): 112-114 .

    Other cited types(7)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (197) PDF downloads (17) Cited by(16)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close